Effects of Escherichia coli Lipopolysaccharide on Chicken Humoral Immune Response

Document Type : Full Research Paper

Authors

1 Department of Pathobiology, Veterinary Faculty of Shahid Chamran University. Ahvaz, Iran.

2 Department Clinical Science, Veterinary Faculty of Shahid Chamran University. Ahvaz, Iran.

3 Department of Pathobiology, Veterinary Faculty of Shahid Chamran University. Ahvaz, Iran

4 Student of Veterinary faculty of ShahidChamran University of Ahvaz, Iran.

Abstract

In this research, extraction, purification and inactivation of Escherichia coli (E. coli) lipopolysaccharide (LPS) were performed with the aim of investigating the effects of inactivated and intact form of LPS on chicken humoral immune response stimulation. Also, the possibility of application of this outer part of cell wall for specific induction of humoral immune response to its reference bacteria was evaluated. The LPS was extracted using Ethylene diamine tetraacetic acid (EDTA). Four doses (10, 25, 50 and 100 µg) of inactivated and intact form of LPS and 100 µL of %20 sheep red blood cell (SRBC) were injected to eight groups of broiler chickens (N=4). The humoral immune responses were evaluated five and 10 days after treatment by haemagglutination assay. The effects of LPS on induction of humoral immune response to the reference bacteria were measured using in-house ELISA. Injection of 10 and 25 µg of LPS significantly (P<0.05) induced the humoral immune response. The inactivated LPS only induced immune responses 10 days after the injection of 100 µg. No significant difference existed between the various groups in antibody titer against E. coli (P<0.05). It is possible to take advantage from Escherichia coli lipopolysaccharide in poultry immunization. Also, evaluation of the side effects and changes of inactivation methods may show the capability of LPS application in animal immunization. In addition, using LPS as a vaccine for E. coli is not suggested.

Keywords

Main Subjects



1- Abbas, A.K., ‎A.H. Lichtman and ‎J.S. Pober. 2000. Cellular and Molecular immunology. Philadelphia London New York. W B Saunders company 204-205.
2- Balboa, J.A., M. Cuello., O. Cabrera., J. Del Campo., M. Lastre., D. Gil., C. Taboada., M. Frinas., M. Hernandez. and O. Perez. 2006. Adjuvant properties of lipopolysaccharide from Neisseria meningitides serogroup B detoxified and conjugated with tetanus toxoid. Vaccine 24: 63–64.
3- Brimacombe, C.A. and J.T. Beatty. 2013. Surface Polysaccharide Extraction and Quantification. Bio Protocol, 3(20), http://www.bio-protocol.org/e934.
4- Cohen, J. 2002. The immunopathogenesis of sepsis, Nature 420: 885-891.
5- Dobrovolskaia, M.A. and S.N. Vogel. 2002. Toll receptors, CD14, and macrophage activation and deactivation by LPS. Microbes and Infection 4: 903–914.
6- Esmaeili, D., M.A. Mobarez., H.A. Salmanian., A. Zavaran. and M. Mahdavi. 2010. Synergistic effect of rCagA and LPS of H. pylori O2 serotype in induction of proper immune response against H. pylori. Journal of Ardabil University of Medical Sciences 8 (1): 1-5 [Persian].
7- Fiske, J.M., A. Ross., R.K. VanDerMeid. and J.C. McMichael. 2001. Arumugham. Method for reducing endotoxin in Moraxella catarrhalis UspA2 protein preparations. Journal of Chromatography 753: 269-278.
8- Laemmli, K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680–685.
9- Liu, X., H, Nie., Y, Zhang., Y, Yao., A, Maitikabili., Y, Qu., S, Shi., C, Chen. and Y, Li. 2013. Cell Surface-Specific N-Glycan Profiling in Breast Cancer. Plos One 8, e72704.
10- Malekpour, A., M. Hedayati., H.R. Ahmadi Ashtiani., M. Rahbar. and H. Rastegar. 2001. Extraction and purification of Salmonella enteritidis lipopolysaccharide and evaluation of the pyrogenic effects in rabbit. Iranian Journal of Medical Microbiology 5(7): 7-13 [Persian].
11- Masuko, T., A. Minami., N. Iwasaki., T. Majima., S. Nishimura. and Y.C. Lee. 2005. Carbohydrate analysis by a phenol-sulfuric acid method in microplate format. Analytical Biochemistry 339: 69–72.
12- Maxwell, J.R., C. Ruby., N.I. Kerkvliet. and A.T. Vella. 2002. Contrasting the roles of costimulation and the natural adjuvant lipopolysaccharide during the induction of T cell immunity. Journal of Immunology 168: 4372–4381.
13- Mohammadi, M., Z. Kianmehr., S. Kaboudanian-Ardestan. and B. Gharegozlou. 2014. Improved immunogenicity of tetanus toxoid by Brucella abortus S19 LPS adjuvant. Iranian Journal of Immunology 11: 189-199.
14- Motahari Nia, U., R. Shapouri., M. Rahnama., M. Ali Ramaei. and M.A. Rezaei. 2001. Evaluation of the immune protection of lipopolysaccharide and protein fraction of Legionella pneumophila bacteria in mice exposed to lethal doses of this bactria. Kordestan Journal of Medical Sciences 16: 20-30 [Persian].
15- Pakzad, A., A. Rezaei., M.J. Rasaei., A. Zavaran-Hosseini., A. Kazemnejad., B. Tabaraei. and S. Rivandi.. 2007. Evaluation of the biological and immunological activities of Brucella abortus lipopolysaccharide. Journal of Ilam University of Medical Sciences 15(2): 14-19 [Persian].
16- Petrovsky, N. and J.C. Aguilar. 2004. Vaccine adjuvants: current state and future trends. Immunology and Cell Biology 82: 488-96.
17- Purkayastha, R.R. and R. Dyson. 1965. Location of the carbohydrate-containing fraction of κ-Casein after gel electrophoresis. Journal of Dairy Science 48: 1419-1422.
18- Seppala, I.J.T. and O. Makela. 1984. Adjuvant effect of bacterial LPS and/or alum precipitation in responses to polysaccharide and protein antigens. Immunology 53: 827-836.
19- Soleimanjahi, H., S. Kaboudanian Ardestani., Z. Kianmehr. and F. Fotouhi. 2014. International Conference on Chemical, Agricultural, and Biological Sciences (ICCABS). Antalya, Turkey 9 -10.
20- Tavakol Afshari, J., A. Sadeghian. and M. Khalili. 2001. Lipopolysaccharide extraction from E. coli cell wall and assess the mitogenic capabilities on B lymphocyte by MTT evaluation. Modares Journal of Medical Sciences 7(1): 39-48 [Persian].
21- Thompson, B.S., P.M. Chilton., J.R. Ward., J.T. Evans. and T.C. Mitchell. 2005. The low-toxicity versions of LPS, MPL adjuvant and RC529, are efficient adjuvants for CD4T cells. Journal of Leukocyte Biology 78: 1273-1280.
22- Ulevitch. R.J. and P.S. Tobias. 1999. Recognition of gram-negative bacteria and endotoxin by the innate immune system. Current Opinion in Immunology 11: 19–22.
23- Velez, I.D., K. Gilchrist., S. Martinez., J.R. Ramirez-Pineda., J.A. Ashman., F.P. Alves., R.N. Coler., L.Y. Bogatzki., S.J. Kahn., A.M. Beckmann., K.D. Cowgill., S.G. Reed. and F.M. Piazza. 2009. Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis. Vaccine 28: 329-337.
24- Walker, J.M. 2002. The protein protocols handbook. 2nd ed. New Jersey, Humana Press 15-21.
25- Wang, X. and P.J. Quinn. 2010. Lipopolysaccharide: Biosynthetic pathway and structure modification. Progress in Lipid Research 49: 97–107.